Why Is My GLP-1 Dose Increasing So Fast? A Chattanooga Doctor Explains
I hear a version of this question almost every week from patients here in Chattanooga: “Why did you just double my dose?” Sometimes it comes from someone new to Summit who started their GLP-1 prescription somewhere else — a telehealth app, a med spa, a Facebook ad that led to a questionnaire and a vial in the mail. They’re not asking because they’re worried about progress. They’re asking because nobody explained the schedule to them in the first place, and now they’re nauseated, dehydrated, and searching the internet for an answer their prescriber never gave them.
That search is what brought you here. So let’s actually answer it.
The question I get asked most: “Why did you just double my dose?”
Dose escalation on semaglutide or tirzepatide is not a formality, and it’s not something a prescriber does because “that’s just the next step in the app.” It’s the single highest-leverage safety decision in GLP-1 therapy. Get it right, and most patients tolerate the medication well. Get it wrong — push too fast, skip a step, ignore what a patient is telling you about their symptoms — and you get the GI distress, the dehydration, the emergency department visits that make the news.
I’ve worked emergency medicine for years. I’ve seen what happens when a patient on a GLP-1 gets dosed faster than their body can adapt. It is avoidable, almost always, and the fix is not complicated: follow the schedule, and adjust it to the person in front of you, not to a subscription-renewal calendar.
What’s actually happening in your body at each step up
Here’s the honest, unglamorous mechanism. GLP-1 receptor agonists work in three main ways: they slow gastric emptying, they suppress glucagon secretion, and they act centrally on hypothalamic appetite centers to reduce hunger signaling.¹ Each of those effects is dose-dependent — meaning the higher the dose, the stronger the effect, and the more your GI system and fluid balance have to adjust to keep up.
Slowed gastric emptying is the mechanism behind the nausea. Food sits in your stomach longer than your body is used to. At a low starting dose, that’s a mild adjustment. Jump too many steps at once, and it becomes vomiting, poor oral intake, and — because you’re eating and drinking less while still losing fluid normally — electrolyte strain. That’s not a rare side effect story. That’s basic physiology responding to a signal it wasn’t given time to adapt to.
This is also why the appetite suppression itself needs a ramp. The central nervous system effect on hunger is powerful. Introduced too quickly, patients stop eating almost entirely for days, which compounds the dehydration and electrolyte problem rather than solving it. The slow step-up isn’t caution for its own sake. It’s giving your gut and your appetite regulation time to adjust together, in the order your biology actually needs.
The titration schedule the big trials actually used — and why it’s not overcaution
Here’s where the “why so slow” complaint runs into a problem: the slow ramp is the same protocol that produced the results these medications are known for.
In STEP 1, the semaglutide trial published in the New England Journal of Medicine in 2021, patients were titrated up over 16 weeks before reaching the 2.4mg maintenance dose — and the group on that schedule averaged 14.9% body weight loss at 68 weeks.² In SURMOUNT-1, the tirzepatide trial published in NEJM in 2022, the titration followed the same principle — gradual step-ups building tolerance before reaching the higher maintenance doses — and patients on the highest dose averaged 20.9% weight loss at 72 weeks.³
Neither trial got those numbers by rushing patients to max dose in month one. They got those numbers because the slow titration let people actually stay on the medication long enough, at a dose their body could tolerate, to see the effect. A prescriber who escalates you faster than that schedule isn’t giving you a shortcut to the same result. They’re increasing your odds of quitting from side effects before you ever get there.
The warning signs of too-fast escalation — and when to call, not wait
If you’re on a GLP-1 right now and something feels off, here’s what should make you call your prescriber the same day, not wait it out:
- Persistent vomiting, or inability to keep fluids down for more than 24 hours
- Dizziness or lightheadedness when standing — a common early sign of dehydration or electrolyte imbalance
- Heart palpitations or new-onset weakness, which can signal a potassium shift
- Abdominal pain that’s severe or worsening, not the mild fullness that’s expected at each step-up
Mild nausea in the first few days after a dose increase is expected and usually resolves. Symptoms severe enough to keep you from eating or drinking normally for more than a day are not something to push through. That’s your body telling you the step-up was too much, too fast — and the fix is almost always to hold or reduce the dose, not to add a second medication to mask the symptom.
Why a name on your chart changes this conversation
Every major GLP-1 telehealth platform — Ro, Hims & Hers, Found, Henry Meds — runs some version of algorithm-driven or high-volume dosing, with a subscription model that benefits from moving you up the dose ladder on schedule, not on your tolerance. Hims & Hers walked back its compounding pharmacy business this year under FDA and manufacturer pressure. Henry Meds saw its CEO depart amid scrutiny of its prescribing practices. These aren’t isolated headlines — they’re a pattern that shows up when the dosing decision is driven by volume and retention rather than by a physician who actually knows the patient.
A checkbox you click yourself is not the same as a physician reviewing your actual history, your GI tolerance, your kidney function, your other medications. At Summit, I personally review every chart. That’s not a marketing line — it’s the reason your titration schedule gets adjusted to you specifically, not to a default protocol running in the background of an app.
What a safe, personalized titration plan looks like at Summit in Chattanooga
At Summit, your dose increase is a decision, not a default. I look at how you tolerated the last step before deciding on the next one. If you’re having more GI symptoms than expected, we hold the dose — sometimes longer than the standard schedule calls for — before moving up. If you’re tolerating it well, we don’t slow you down artificially either. The goal is the same one STEP 1 and SURMOUNT-1 were built around: get you to an effective, tolerable dose you can actually stay on, safely, for the long run.
Chattanooga patients come to Summit after a fast-dosed telehealth experience left them sick, discouraged, or both. The medication wasn’t the problem. The dosing plan was.
Ready to start? Apply at summitmetabolichealth.com/apply
This post is educational and does not replace individualized medical advice. If you’re experiencing severe symptoms on a GLP-1 medication, contact your prescriber or seek emergency care.
¹ Drucker DJ. “Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.” Cell Metabolism, 2018. ² Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021 (STEP 1). ³ Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022 (SURMOUNT-1).